|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INPP5F |
Gene summary for INPP5F |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INPP5F | Gene ID | 22876 |
| Gene name | inositol polyphosphate-5-phosphatase F | |
| Gene Alias | MSTP007 | |
| Cytomap | 10q26.11 | |
| Gene Type | protein-coding | GO ID | GO:0001881 | UniProtAcc | Q9Y2H2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22876 | INPP5F | LZE4T | Human | Esophagus | ESCC | 1.72e-06 | 2.07e-01 | 0.0811 |
| 22876 | INPP5F | LZE24T | Human | Esophagus | ESCC | 6.35e-10 | 3.07e-01 | 0.0596 |
| 22876 | INPP5F | P2T-E | Human | Esophagus | ESCC | 2.25e-12 | 2.96e-01 | 0.1177 |
| 22876 | INPP5F | P4T-E | Human | Esophagus | ESCC | 2.07e-18 | 5.21e-01 | 0.1323 |
| 22876 | INPP5F | P5T-E | Human | Esophagus | ESCC | 2.02e-25 | 4.66e-01 | 0.1327 |
| 22876 | INPP5F | P8T-E | Human | Esophagus | ESCC | 4.16e-10 | 9.04e-02 | 0.0889 |
| 22876 | INPP5F | P9T-E | Human | Esophagus | ESCC | 3.11e-09 | 1.55e-01 | 0.1131 |
| 22876 | INPP5F | P11T-E | Human | Esophagus | ESCC | 8.17e-04 | 3.22e-01 | 0.1426 |
| 22876 | INPP5F | P12T-E | Human | Esophagus | ESCC | 7.55e-08 | 2.06e-01 | 0.1122 |
| 22876 | INPP5F | P15T-E | Human | Esophagus | ESCC | 2.50e-10 | 2.92e-01 | 0.1149 |
| 22876 | INPP5F | P16T-E | Human | Esophagus | ESCC | 2.20e-08 | 1.76e-01 | 0.1153 |
| 22876 | INPP5F | P19T-E | Human | Esophagus | ESCC | 1.05e-07 | 5.44e-01 | 0.1662 |
| 22876 | INPP5F | P20T-E | Human | Esophagus | ESCC | 5.72e-06 | 2.20e-01 | 0.1124 |
| 22876 | INPP5F | P21T-E | Human | Esophagus | ESCC | 2.20e-17 | 4.20e-01 | 0.1617 |
| 22876 | INPP5F | P22T-E | Human | Esophagus | ESCC | 1.26e-09 | 1.72e-01 | 0.1236 |
| 22876 | INPP5F | P23T-E | Human | Esophagus | ESCC | 8.28e-06 | 2.23e-01 | 0.108 |
| 22876 | INPP5F | P24T-E | Human | Esophagus | ESCC | 5.10e-17 | 3.10e-01 | 0.1287 |
| 22876 | INPP5F | P26T-E | Human | Esophagus | ESCC | 1.80e-16 | 2.96e-01 | 0.1276 |
| 22876 | INPP5F | P27T-E | Human | Esophagus | ESCC | 6.76e-17 | 2.69e-01 | 0.1055 |
| 22876 | INPP5F | P28T-E | Human | Esophagus | ESCC | 5.04e-24 | 4.33e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003238618 | Esophagus | ESCC | regulation of intracellular transport | 243/8552 | 337/18723 | 3.20e-23 | 7.25e-21 | 243 |
| GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
| GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
| GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
| GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
| GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
| GO:0001933111 | Esophagus | ESCC | negative regulation of protein phosphorylation | 213/8552 | 342/18723 | 3.54e-10 | 9.76e-09 | 213 |
| GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
| GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
| GO:003109910 | Esophagus | ESCC | regeneration | 122/8552 | 198/18723 | 4.26e-06 | 4.57e-05 | 122 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:004311218 | Esophagus | ESCC | receptor metabolic process | 104/8552 | 166/18723 | 7.44e-06 | 7.37e-05 | 104 |
| GO:00324565 | Esophagus | ESCC | endocytic recycling | 51/8552 | 73/18723 | 2.47e-05 | 2.10e-04 | 51 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:000689818 | Esophagus | ESCC | receptor-mediated endocytosis | 142/8552 | 244/18723 | 5.22e-05 | 4.05e-04 | 142 |
| GO:00507322 | Esophagus | ESCC | negative regulation of peptidyl-tyrosine phosphorylation | 42/8552 | 59/18723 | 6.35e-05 | 4.84e-04 | 42 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| INPP5F | SNV | Missense_Mutation | novel | c.1364N>A | p.Arg455His | p.R455H | Q9Y2H2 | protein_coding | deleterious(0) | possibly_damaging(0.539) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| INPP5F | SNV | Missense_Mutation | novel | c.1851N>A | p.Phe617Leu | p.F617L | Q9Y2H2 | protein_coding | tolerated(0.49) | probably_damaging(0.992) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| INPP5F | SNV | Missense_Mutation | rs763846879 | c.2269N>A | p.Glu757Lys | p.E757K | Q9Y2H2 | protein_coding | tolerated(0.08) | possibly_damaging(0.643) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| INPP5F | SNV | Missense_Mutation | c.1478T>C | p.Leu493Ser | p.L493S | Q9Y2H2 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| INPP5F | SNV | Missense_Mutation | c.1378N>A | p.Asp460Asn | p.D460N | Q9Y2H2 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| INPP5F | SNV | Missense_Mutation | novel | c.3179C>T | p.Ser1060Leu | p.S1060L | Q9Y2H2 | protein_coding | deleterious_low_confidence(0) | benign(0.024) | TCGA-EW-A1IX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD |
| INPP5F | deletion | Frame_Shift_Del | c.1190delN | p.Phe398SerfsTer20 | p.F398Sfs*20 | Q9Y2H2 | protein_coding | TCGA-A1-A0SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | |||
| INPP5F | insertion | Frame_Shift_Ins | novel | c.1291_1292insGTTTCACCATGTTGGCCAGGCTGGTCTC | p.Asp431GlyfsTer14 | p.D431Gfs*14 | Q9Y2H2 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| INPP5F | SNV | Missense_Mutation | c.3160N>T | p.His1054Tyr | p.H1054Y | Q9Y2H2 | protein_coding | tolerated_low_confidence(0.11) | benign(0) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| INPP5F | SNV | Missense_Mutation | novel | c.1940N>T | p.Ser647Phe | p.S647F | Q9Y2H2 | protein_coding | deleterious(0.04) | possibly_damaging(0.458) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |